As Vertex’s pivotal pain readout looms, non-opioid drug development faces a reckoning
Many drug developers have abandoned the search for new pain medicines. But the outlook of the field, experts say, could change from a pair of late-stage clinical trials testing Vertex Pharmaceuticals’ non-opioid compound.
There hasn’t been a new class of pain drug in decades, according to a Vertex press release. Vertex’s drug stands as one of the few in late-stage studies, with results expected later this year or early next year. If successful, the data readout could reinvigorate pain drug development after the likes of Biogen, Roche and Pfizer exited the space.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
